Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma

Tracking Information
First Submitted Date ICMJE	November 30, 2006
First Posted Date ICMJE	December 4, 2006
Last Update Posted Date	November 13, 2017
Actual Study Start Date ICMJE	August 30, 2006
Actual Primary Completion Date	July 15, 2009 (Final data collection date for primary outcome measure)
Current Primary Outcome Measures ICMJE; (submitted: October 8, 2009)	Adverse events, changes from baseline in physical examination and clinical laboratory parameters12-lead ECGAssessment of pharmacokinetic endpoints of 506U78, ara-G and intracellular ara-GTP concentration. [ Time Frame: Day 21 ]
Original Primary Outcome Measures ICMJE; (submitted: December 1, 2006)	Adverse events Changes from baseline in physical examination and clinical laboratory parameters 12-lead ECG Assessment of pharmacokinetic endpoints of 506U78, ara-G and intracellular ara-GTP concentration.
Change History	Complete list of historical versions of study NCT00406757 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ICMJE; (submitted: October 8, 2009)	Evaluation of response (e.g., CR, CR*) in patients with bone marrow involvement. [ Time Frame: Day 21 ]
Original Secondary Outcome Measures ICMJE; (submitted: December 1, 2006)	Evaluation of response (e.g., CR, CR*) in patients with bone marrow involvement.
Current Other Outcome Measures ICMJE	Not Provided
Original Other Outcome Measures ICMJE	Not Provided
Descriptive Information
Brief Title ICMJE	Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma
Official Title ICMJE	Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.
Brief Summary	In Japan, patients with relapsed or refractory T-ALL/T-LBL represent an extremely small patient population. While the small number of patients presents a practical limitation to the size of a clinical trial, patients whose disease has not responded to or has relapsed after treatment with multiple prior chemotherapy regimens have no accepted standard therapies available. Japanese leukemia experts have expressed interest in evaluating 506U78 in Japanese patients with relapsed or refractory T-ALL/T-LBL. In order to obtain safety, tolerability, and pharmacokinetic data of 506U78 in Japanese patients, this study is designed to maximize the contribution of each available patient.
Detailed Description	Not Provided
Study Type ICMJE	Interventional
Study Phase	Phase 1
Study Design ICMJE	Allocation: Non-Randomized; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition ICMJE	Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic
Intervention ICMJE	Drug: Nelarabine injection 400mg/m2 Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5. Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5.; Drug: Nelarabine injection 650mg/m2 Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.; Drug: Nelarabine injection 1000mg/m2 Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5. Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.; Drug: Nelarabine injection 1500mg/m2 Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Study Arms	Active Comparator: Pediatric Arm 1 Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose. Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose. Intervention: Drug: Nelarabine injection 400mg/m2; Active Comparator: Pediatric Arm 2 Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose. Intervention: Drug: Nelarabine injection 650mg/m2; Active Comparator: Adult Arm 1 Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose. Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose. Intervention: Drug: Nelarabine injection 1000mg/m2; Active Comparator: Adult Arm 2 Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose. Intervention: Drug: Nelarabine injection 1500mg/m2; Active Comparator: Pediatric Arm 3 Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5. Intervention: Drug: Nelarabine injection 650mg/m2
Publications *	Horibe K, Takimoto T, Yokozawa T, Makimoto A, Kobayashi Y, Ogawa C, Ohno R, Koh N, Katsura K, Tobinai K. [Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL]. Rinsho Ketsueki. 2011 Jun;52(6):406-15.
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status ICMJE	Completed
Actual Enrollment ICMJE; (submitted: October 8, 2009)	13
Original Enrollment ICMJE; (submitted: December 1, 2006)	12
Actual Study Completion Date	July 15, 2009
Actual Primary Completion Date	July 15, 2009 (Final data collection date for primary outcome measure)
Eligibility Criteria ICMJE	Inclusion Criteria: Histologic or cytogenetic documented diagnosis of T-ALL or T-LBL.; Disease that is refractory to at least one prior chemotherapy regimen, or has relapsed following complete remission to at least one prior chemotherapy regimen.; At least 4 weeks since the last dose of prior last chemotherapy, or radiotherapy before beginning treatment with 506U78 (2 weeks is permitted if growth of blast cells is significant).; Adequate function of other organ systems as measured as follows.Serum creatinine is less than 1.5 times of upper limit of normal and estimated creatinine clearance >=50 mL/min. Hepatic transaminases (SGPT and SGOT) <=3 x upper limit of normal, bilirubin is less than 1.5 times of upper limit of normal(<=5 x upper limit of normal if it is related by T-ALL or T-LBL).; Adequate performance status (ECOG-PS<=2).; Capable of giving informed consent which includes compliance with the requirements and restrictions listed in the consent form.; Patient is willing to accept hospitalization during the blood sampling for pharmacokinetic measurement (i.e., Cohort 1: for pharmacokinetic sample collection during both cycle 1 and 2; and Cohort 2: for pharmacokinetic sample collection during cycle 1).; Female subjects who are of child-bearing potential must have a negative pregnancy test at the Screening Visit and agree to utilize contraceptive methods during participation in the study and for at least six months following the last dose of 506U78 Injection. Female subjects may be defined as of non-child-bearing potential if they are physiologically incapable of becoming pregnant, including any female who is post-menopausal. For purposes of this study, postmenopausal is defined as one year without menses. Exclusion Criteria: Active infection at time of treatment.; Concurrent disease or condition that would make the subject inappropriate for study participation.; Receiving any other anticancer agents or enrolled on any investigational study during the course of the study.; Patients must have recovered to Grade I or less toxicity of all previous chemotherapy prior to treatment.; History of seizure disorder within one year prior to the date of informed consent.; Pregnancy (as demonstrated by a positive pregnancy test at pre-study/screening) or breastfeeding. Fertile women and men must practice adequate contraception throughout the study and at least 6 month after the last dose of study drug.
Sex/Gender	Sexes Eligible for Study: All
Ages	up to 64 Years (Child, Adult)
Accepts Healthy Volunteers	No
Contacts ICMJE	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries ICMJE	Japan
Removed Location Countries
Administrative Information
NCT Number ICMJE	NCT00406757
Other Study ID Numbers ICMJE	PGA105446
Has Data Monitoring Committee	Not Provided
U.S. FDA-regulated Product	Not Provided
IPD Sharing Statement	Not Provided
Responsible Party	GlaxoSmithKline
Study Sponsor ICMJE	GlaxoSmithKline
Collaborators ICMJE	Not Provided
Investigators ICMJE	Study Director: GSK Clinical Trials GlaxoSmithKline
PRS Account	GlaxoSmithKline
Verification Date	November 2017
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP